U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C19H20N6O.2C3H6O2
Molecular Weight 496.5588
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of IMIDOCARB DIPROPIONATE

SMILES

CCC(O)=O.CCC(O)=O.O=C(NC1=CC=CC(=C1)C2=NCCN2)NC3=CC=CC(=C3)C4=NCCN4

InChI

InChIKey=AFGQXWSHYUHHNV-UHFFFAOYSA-N
InChI=1S/C19H20N6O.2C3H6O2/c26-19(24-15-5-1-3-13(11-15)17-20-7-8-21-17)25-16-6-2-4-14(12-16)18-22-9-10-23-18;2*1-2-3(4)5/h1-6,11-12H,7-10H2,(H,20,21)(H,22,23)(H2,24,25,26);2*2H2,1H3,(H,4,5)

HIDE SMILES / InChI
Imidocarb is a carbanilide derivative with antiprotozoal activity. It is usually administered as the dipropionate salt. Imidocarb is a drug sold under the brand name Imizol and is used to treat canine ehrlichiosis. wo mechanisms of action have been proposed: As the effect of imidocarb on Trypanosoma brucei is antagonized by excess polyamines, it is has been suggested that imidocarb interferes with their production and/or use. Imidocarb blocks the entry of inositol into erythrocytes containing Babesia, resulting in starvation of the parasite. It is generally accepted in that imidocarb has anticholinesterase activity.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
590.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Imizol

Approved Use

For the treatment of babesiosis in dogs with clinical signs and/or demonstrated Babesia organisms in the blood.

Launch Date

1997
Curative
IMIDOCARB

Approved Use

For treatment of babesiosis in cattle and horses

Launch Date

2001
PubMed

PubMed

TitleDatePubMed
Cationic antitrypanosomal and other antimicrobial agents in the therapy of experimental Pneumocystis carinii pneumonia.
1988 Jun
Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs.
1992 Sep
Determination of whole blood cholinesterase in different animal species using specific substrates.
2001 Jun
Depletion and bioavailability of imidocarb residues in sheep and goat tissues.
2002 Apr
Electron microscopic investigations on stages of dog piroplasms cultured in vitro: Asian isolates of Babesia gibsoni and strains of B. canis from France and Hungary.
2002 Jan
Residual effect of antibabesial drugs on the live redwater blood vaccines.
2002 Oct
Pharmacokinetics of imidocarb dipropionate in horses after intramuscular administration.
2002 Sep
Effects of imidocarb dipropionate in cats with chronic haemobartonellosis.
2002 Summer
Evaluation of certain veterinary drug residues in food.
2003
Naturally acquired babesiosis in a reindeer (Rangifer tarandus tarandus) herd in Great Britain.
2003 Feb
Humoral immunity and reinfection resistance in dogs experimentally inoculated with Babesia canis and either treated or untreated with imidocarb dipropionate.
2003 Jun 25
In-vivo therapeutic efficacy trial with artemisinin derivative, buparvaquone and imidocarb dipropionate against Babesia equi infection in donkeys.
2003 Nov
Concurrent bartonellosis and babesiosis in a dog with persistent thrombocytopenia.
2003 Nov 1
Imidocarb, a potent anti-protozoan drug, up-regulates interleukin-10 production by murine macrophages.
2003 Sep 19
[Autochthonous babesiosis in dogs in the Netherlands?].
2004 May 1
First isolation and molecular characterization of Ehrlichia canis in Spain.
2004 Nov 10
Detection and molecular characterization of a novel large Babesia species in a dog.
2004 Oct 5
[A literature review of equine piroplasmosis after an episode of acute babesiosis in a Dutch Standardbred foal after a stay in Normandy].
2005 Dec 1
Autochthonous canine babesiosis in The Netherlands.
2005 Jul 15
Identification of anti-babesial activity for four ethnoveterinary plants in vitro.
2005 Jun 10
Clinical and clinicopathological changes in 6 healthy ponies following intramuscular administration of multiple doses of imidocarb dipropionate.
2005 Mar
Effective imidocarb dipropionate therapy for Babesia shortti in falcons.
2006 Feb 18
Pharmacokinetics and mammary elimination of imidocarb in sheep and goats.
2006 Jul
Failure of imidocarb dipropionate to clear experimentally induced Ehrlichia canis infection in dogs.
2006 Jul-Aug
Flow cytometric evaluation of selected antimicrobial efficacy for clearance of Anaplasma marginale in short-term erythrocyte cultures.
2006 Jun
Effect of imidocarb and levamisole on the experimental infection of BALB/c mice by Leishmania (Leishmania) amazonensis.
2006 Jun 30
Clinicopathological changes and effect of imidocarb therapy in dogs experimentally infected with Babesia canis.
2006 Mar
Canine babesiosis in France.
2006 May 31
Chemotherapy against babesiosis.
2006 May 31
Clinical manifestations of canine babesiosis in Hungary (63 cases).
2006 Sep
Comparison of the efficacy of enrofloxacin, imidocarb, and oxytetracycline for clearance of persistent Anaplasma marginale infections in cattle.
2006 Winter
Pharmacokinetics and bioavailability of imidocarb dipropionate in swine.
2007 Aug
Molecular characterisation of Babesia gibsoni infection from a pit-bull terrier pup recently imported into South Africa.
2007 Mar
Therapeutic and prophylactic efficacy of imidocarb dipropionate on experimental Babesia ovis infection of lambs.
2007 Oct 21
[Dogs babesiosis--still actually problem].
2008
Canine vector-borne diseases in Brazil.
2008 Aug 8
Treatment of Mycoplasma wenyonii infection in cows with imidocarb dipropionate injection-acupuncture.
2008 Dec
Detection of persistent Cytauxzoon felis infection by polymerase chain reaction in three asymptomatic domestic cats.
2008 Jul
Putative clinical piroplasmosis in a Burchell's zebra (Equus quagga burchelli).
2009 Dec
Diagnosis and treatment of Babesia odocoilei in captive reindeer (Rangifer tarandus tarandus) and recognition of three novel host species.
2009 Mar
Residue depletion of imidocarb in Swine tissue.
2009 Mar 25
Canine babesiosis: from molecular taxonomy to control.
2009 Mar 26
Babesia and its hosts: adaptation to long-lasting interactions as a way to achieve efficient transmission.
2009 Mar-Apr
Failure of imidocarb dipropionate to eliminate Hepatozoon canis in naturally infected dogs based on parasitological and molecular evaluation methods.
2010 Aug 4
First case of babesiosis caused by Babesia canis canis in a dog from Norway.
2010 Aug 4
Detection of Babesia divergens in southern Norway by using an immunofluorescence antibody test in cow sera.
2010 Oct 6
Patents

Sample Use Guides

In Vivo Use Guide
Use intramuscularly or subcutaneously at a rate of 6.6 mg/kg (3 mg/lb) body weight. Repeat the dose in two (2) weeks, for a total of two (2) treatments.
Route of Administration: Other
In Vitro Use Guide
The concentration of Imidocarb causing 50% inhibition of [3H]hypoxanthine incorporation (ID50 value) by Babesia bovis (Lismore and Samford isolates) cultured in vitro for Imidocarb was determined to be 3 ng/ml (8.6 nM).
Name Type Language
IMIDOCARB DIPROPIONATE
GREEN BOOK   MART.  
Common Name English
N,N'-BIS(3-(4,5-DIHYDRO-1H-IMIDAZOL-2-YL)PHENYL)UREA DIPROPIONATE
Systematic Name English
3,3'-DI-2-IMIDAZOLIN-2-YLCARBANILIDE DIPROPIONATE
Common Name English
IMIDOCARB DIPROPIONATE [GREEN BOOK]
Common Name English
IMIDOCARB DIPROPIONATE [MART.]
Common Name English
Classification Tree Code System Code
CFR 21 CFR 522.1156
Created by admin on Fri Dec 15 15:56:29 GMT 2023 , Edited by admin on Fri Dec 15 15:56:29 GMT 2023
CFR 21 CFR 522.1155
Created by admin on Fri Dec 15 15:56:29 GMT 2023 , Edited by admin on Fri Dec 15 15:56:29 GMT 2023
Code System Code Type Description
EPA CompTox
DTXSID4046604
Created by admin on Fri Dec 15 15:56:29 GMT 2023 , Edited by admin on Fri Dec 15 15:56:29 GMT 2023
PRIMARY
WIKIPEDIA
Imidocarb dipropionate
Created by admin on Fri Dec 15 15:56:29 GMT 2023 , Edited by admin on Fri Dec 15 15:56:29 GMT 2023
PRIMARY
RXCUI
1740238
Created by admin on Fri Dec 15 15:56:29 GMT 2023 , Edited by admin on Fri Dec 15 15:56:29 GMT 2023
PRIMARY
DAILYMED
ZSM1M03SHC
Created by admin on Fri Dec 15 15:56:29 GMT 2023 , Edited by admin on Fri Dec 15 15:56:29 GMT 2023
PRIMARY
PUBCHEM
9983292
Created by admin on Fri Dec 15 15:56:29 GMT 2023 , Edited by admin on Fri Dec 15 15:56:29 GMT 2023
PRIMARY
ECHA (EC/EINECS)
259-791-8
Created by admin on Fri Dec 15 15:56:29 GMT 2023 , Edited by admin on Fri Dec 15 15:56:29 GMT 2023
PRIMARY
NCI_THESAURUS
C76007
Created by admin on Fri Dec 15 15:56:29 GMT 2023 , Edited by admin on Fri Dec 15 15:56:29 GMT 2023
PRIMARY
CAS
55750-06-6
Created by admin on Fri Dec 15 15:56:29 GMT 2023 , Edited by admin on Fri Dec 15 15:56:29 GMT 2023
PRIMARY
SMS_ID
300000023751
Created by admin on Fri Dec 15 15:56:29 GMT 2023 , Edited by admin on Fri Dec 15 15:56:29 GMT 2023
PRIMARY
FDA UNII
ZSM1M03SHC
Created by admin on Fri Dec 15 15:56:29 GMT 2023 , Edited by admin on Fri Dec 15 15:56:29 GMT 2023
PRIMARY
MESH
C031719
Created by admin on Fri Dec 15 15:56:29 GMT 2023 , Edited by admin on Fri Dec 15 15:56:29 GMT 2023
PRIMARY
DRUG BANK
DBSALT001684
Created by admin on Fri Dec 15 15:56:29 GMT 2023 , Edited by admin on Fri Dec 15 15:56:29 GMT 2023
PRIMARY